MANHASSET, NY (PRWEB) July 25, 2013
The Feinstein Institute for Medical Research announced today it will receive a $250,000 grant aimed at gaining a better understanding of chronic lymphocytic leukemia (CLL) and other blood cancers.
The two-year grant from the Lymphoma Research Foundation (LRF), the nation’s largest non-profit organization devoted to funding innovative lymphoma research, was awarded to
Nicholas Chiorazzi, MD, head of the Karches Center for Chronic Lymphocytic Leukemia Research at the Feinstein Institute. Dr. Chiorazzi’s lab and that of his collaborator, Dr. Matthew D. Scharff at the Albert Einstein College of Medicine in the Bronx, will utilize the funds to research gene expression and DNA methylation signatures linked to in vivo CLL/small lymphocytic lymphoma B-cell kinetics and outcome.
“I am grateful to the Lymphoma Research Foundation for supporting this research so that Dr. Scharff and I can work to better understand CLL and ultimately find a new, improved treatment for the devastating disease,” said Dr. Chiorazzi.
The grant received from LRF is a portion of a $2.15 million grant divided among seven scientists investigating the biology of or new therapies for lymphoma.
“As evident in our recent funding of more than $2 million in research, the Lymphoma Research Foundation is dedicated to finding a cure for lymphoma through an aggressively funded research program,” said Diane Blum, LRF chief executive officer. “We remain grateful to our supporters whose generosity enables the Foundation to work toward its mission of eradicating lymphoma through innovative research.”
Recommendations for research funding were made by the LRF Scientific Advisory Board, which is comprised of t
Copyright©2012 Vocus, Inc.
All rights reserved